VICO.ST STO
Vicore Pharma Holding AB (publ)
1W: -2.9%
1M: -14.5%
3M: -40.6%
YTD: -14.2%
1Y: -14.3%
3Y: -37.4%
5Y: -53.5%
kr 9.32 ($0.93)
-0.09 (-0.96%)
Weekly Expected Move ±5.1%
kr 8
kr 9
kr 9
kr 10
kr 10
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$4M
-96.5% ▼
Gross Profit
$4M
-96.5% ▼
Operating Income
-$454M
-134.0% ▼
Net Income
-$477M
-183.1% ▼
EPS (Diluted)
$-1.99
-165.3% ▼
EBITDA
-$454M
-172.7% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $109M | $4M |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | -96.5% |
| Cost of Revenue | $4M | $4M | $3M | $0 | $0 |
| Gross Profit | -$4M | -$4M | -$3M | $109M | $4M |
| Gross Margin | — | — | — | 100.0% | 100.0% |
| R&D Expenses | $272M | $250M | $273M | $249M | $390M |
| SG&A Expenses | $22M | $38M | $45M | $50M | $68M |
| Operating Expenses | $293M | $287M | $322M | $304M | $458M |
| Operating Income | -$295M | -$291M | -$322M | -$194M | -$454M |
| Operating Margin | — | — | — | -177.6% | -11905.8% |
| Interest Expense | $11K | $8K | $358K | $8K | $50M |
| Income Before Tax | -$297M | -$289M | -$311M | -$169M | -$477M |
| Tax Expense | -$254K | -$384K | -$384K | -$256K | $0 |
| Net Income | -$296M | -$288M | -$311M | -$169M | -$477M |
| Net Margin | — | — | — | -154.2% | -12509.1% |
| EPS (Diluted) | $-4.25 | $-3.99 | $-3.22 | $-0.75 | $-1.99 |
| EBITDA | -$290M | -$286M | -$317M | -$167M | -$454M |
| Shares Outstanding | 70M | 72M | 97M | 225M | 240M |